Prosecution Insights
Last updated: October 02, 2026

Emory University

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

40 pending office actions • 19 art units • 39 examiners • 0 of 40 (0%) have an AI response strategy ready • 27 patents granted in the last 365 days

Analysis

Emory University has 41 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 40 distinct examiners, with GALSTER, SAMUEL LEONARD serving as the busiest examiner with 2 pending office actions. The 41 pending office actions are distributed across 19 distinct art units.

The involvement of 40 distinct examiners for the actions indicates a relationship where almost every examiner handles a single case. GALSTER, SAMUEL LEONARD is the only examiner managing more than one case, with 2 of the total pending actions. The 19 distinct art units show that the portfolio covers a variety of technical sub-sectors. With 40 distinct examiners, the university's prosecution is decentralized, requiring management of many different examiner relationships. This distribution means that no single examiner or art unit has a dominant influence over the 41 total pending actions.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

40
Total Pending OAs
32
Non-Final OAs
7
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
1
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 7 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

21
Hard (52%)
15
Medium (38%)
3
Easy (8%)
1
Unknown (2%)

Rejection Statute Mix

BucketCases
§101 + other4 (10%)
§103 only7 (18%)
§102 only2 (5%)
§112 only3 (8%)
Double-patenting + other6 (15%)
Multi-statute (no §101)17 (42%)
No statute on record1 (2%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

18
Life Sciences
45% of docket
1
Information Tech
2% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
6
Mechanical / Eng
15% of docket
15
Business / Other
38% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

400 h
Manual time on pending OAs
80 h
Time saved (low, 20%)
140 h
Time saved (mid, 35%)
3.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GALSTER, SAMUEL LEONARD 2 50.9% +43.2%
MATTHEWS, WILLIAM H 1 66.7% +21.6%
KUO, JONATHAN T 1 72.3% +28.3%
NAH, JONGBONG 1 75.2% +17.5%
OKEKE, IZUNNA 1 81.8% +15.5%
RICCI, CRAIG D 1 53.5% +52.7%
HUYNH, VAN D 1 87.0% +13.4%
LUKJAN, SEBASTIAN X 1 76.3% +40.3%
STOCKTON, LAURA LYNNE 1 75.2% +33.7%
BANERJEE, KOYELI 1 50.0% +0.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18853930 DEVICES, SYSTEMS AND METHODS FOR SECURING COMMUNICATION INTEGRITY OKEKE, IZUNNA —

Hard Cases (21)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18000865 DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION KIM, TAEYOON 49d overdue
18558026 CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE ARMATO JR, DENNIS IGNATIUS 6d
18564391 SYSTEMS AND METHODS OF USING NANOMEMBRANE ELECTRONICS SOLOMON, JOSHUA BRENDON 48d
18993727 RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION KUO, JONATHAN T —
18853643 Indolium Compounds for Treating Cancer RICCI, CRAIG D —
18901408 MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS HUYNH, VAN D —
18819710 SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS LUKJAN, SEBASTIAN X —
18742659 RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions BANERJEE, KOYELI —

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
19380466 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO GALSTER, SAMUEL LEONARD —
19304178 Cardiac Valve Leaflet Enhancer Devices and Systems MATTHEWS, WILLIAM H —
18993727 RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION KUO, JONATHAN T —
18961390 Systems and Methods for Correcting Intravoxel and/or Voxel Inhomogeneity NAH, JONGBONG —
18853930 DEVICES, SYSTEMS AND METHODS FOR SECURING COMMUNICATION INTEGRITY OKEKE, IZUNNA —
18853643 Indolium Compounds for Treating Cancer RICCI, CRAIG D —
18901408 MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS HUYNH, VAN D —
18819710 SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS LUKJAN, SEBASTIAN X —

Top Art Units

Art UnitApps
1693 3
3774 2
3792 2
1626 2
1631 2
2408 1
3791 1
1634 1
1691 1
1612 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19380466 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO GALSTER, SAMUEL LEONARD 1693 §103 Final Rejection — Pending Nov 05, 2025
19304178 Cardiac Valve Leaflet Enhancer Devices and Systems MATTHEWS, WILLIAM H 3774 Other Non-Final OA — Pending Aug 19, 2025
18993727 RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION KUO, JONATHAN T — §102§103§112 Non-Final OA — Pending Jan 13, 2025
18961390 Systems and Methods for Correcting Intravoxel and/or Voxel Inhomogeneity NAH, JONGBONG — §103 Non-Final OA — Pending Nov 26, 2024
18853930 DEVICES, SYSTEMS AND METHODS FOR SECURING COMMUNICATION INTEGRITY OKEKE, IZUNNA 2408 §102 Non-Final OA — Pending Oct 03, 2024
18853643 Indolium Compounds for Treating Cancer RICCI, CRAIG D — §102§112 Non-Final OA — Pending Oct 02, 2024
18901408 MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS HUYNH, VAN D — §102§103 Non-Final OA — Pending Sep 30, 2024
18819710 SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS LUKJAN, SEBASTIAN X 3792 §101§102§103§112 Final Rejection — Pending Aug 29, 2024
18756360 Nucleoside Prodrugs and Uses Related Thereto STOCKTON, LAURA LYNNE — §112DP Non-Final OA — Pending Jun 27, 2024
18742659 RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions BANERJEE, KOYELI — §103§112 Non-Final OA — Pending Jun 13, 2024
18680912 Methods of Producing Astrocytes or Promoting Astrocyte Development and Cell Culture Compositions Related Thereto GRABER, JAMES J — §102§112 Non-Final OA — Pending May 31, 2024
18709256 Prodrugs of Neurosteroid Analogs and Uses Thereof JAVANMARD, SAHAR — §112 Non-Final OA — Pending May 10, 2024
18709395 Prodrugs of Neurosteroid Analogs and Uses Thereof CHAO, ALLEN — §112DP Non-Final OA — Pending May 10, 2024
18702922 TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES CHO, DAVID H — §103§112DP Non-Final OA — Pending Apr 19, 2024
18698693 3D AUXETIC STRUCTURES AND FABRICATION METHODS THEREOF STEWART, ALVIN J — §102 Non-Final OA — Pending Apr 04, 2024
18612453 SYSTEMS AND METHODS FOR DRIVING NEURAL ACTIVITY TO CONTROL BRAIN SIGNALING AND GENE EXPRESSION DORNA, CARRIE R 3791 §112DP Non-Final OA — Pending Mar 21, 2024
18292483 Methods of Improving Therapeutic Efficacy of Mesenchymal Stromal Cells for Treatment of Osteoarthritis KASAYAN, KATRIEL BARCELLANO 1634 §101§103§112 Non-Final OA — Pending Jan 26, 2024
18291630 PHOSPHATE PRODRUGS OF CANNABINOIDS RAHMANI, NILOOFAR 1691 §102§112 Non-Final OA — Pending Jan 24, 2024
18580674 BAK ACTIVATORS, PHARMACEUTICAL COMPOSITIONS, AND USES IN TREATING CANCER HAVLIN, ROBERT H 1626 §102§103§112 Non-Final OA — Pending Jan 19, 2024
18579142 T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof GODDARD, LAURA B — §101§102§103§112 Non-Final OA — Pending Jan 12, 2024
18572536 3-Iodopropyl-1,2,3-Triazol-1-yl, 3-Bromopropyl-1,2,3-Triazol-1-yl, and Derivatives for Uses in Labeling LEWOCZKO, EVAN MICHAEL 1612 §103DP Non-Final OA — Pending Dec 20, 2023
18542154 SYSTEMS, APPARATUSES, AND METHODS TO MEASURE ADHESION OF BLOOD CELLS IN MICROFLUIDIC CHANNELS JARRETT, LORE RAMILLANO — §102§103§112 Non-Final OA — Pending Dec 15, 2023
18542096 SYSTEMS AND METHODS TO MEASURE OCCLUSION OF BLOOD CELLS IN MICROFLUIDIC CHANNELS ORANGE, DAVID BENJAMIN — §102§112 Non-Final OA — Pending Dec 15, 2023
18527046 Catheter Retention Device STIMPERT, PHILIP EARL 3783 §102§103§112 Non-Final OA — Pending Dec 01, 2023
18564391 SYSTEMS AND METHODS OF USING NANOMEMBRANE ELECTRONICS SOLOMON, JOSHUA BRENDON 3792 §101§103 Non-Final OA 48d Pending Nov 27, 2023
18561673 JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy LANDSMAN, ROBERT S — §112 Non-Final OA — Pending Nov 16, 2023
18510060 Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies SINGH, ANOOP KUMAR 1632 §103§112DP Non-Final OA — Pending Nov 15, 2023
18289868 ISOLATION AND ANALYSIS OF SINGLE CELLS SECRETING MOLECULES USING HETEROFUNCTIONAL PARTICLES LUSI, ELLIS FOLLETT 1677 §102§112 Non-Final OA — Pending Nov 07, 2023
18558874 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO GALSTER, SAMUEL LEONARD 1693 §103 Final Rejection — Pending Nov 03, 2023
18558026 CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE ARMATO JR, DENNIS IGNATIUS 1651 §102§112 Final Rejection 6d Pending Oct 30, 2023
18285789 THIONUCLEOSIDES AS ANTIVIRAL AGENTS LAU, JONATHAN S 1693 §103§112 Non-Final OA — Pending Oct 05, 2023
18274682 Rotatable Hip Prosthesis DUDDEN, TERESA MARIE 3774 §112 Final Rejection — Pending Jul 27, 2023
18034520 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke KUCKLA, ANNA GRACE 1626 §103§112 Non-Final OA — Pending Apr 28, 2023
18176021 CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION LEONARD, ARTHUR S 1631 §103 Final Rejection — Pending Feb 28, 2023
18111350 RESPONSE-GUIDED HCV THERAPY CHANDRAKUMAR, NIZAL S 1625 §103§112 Non-Final OA — Pending Feb 17, 2023
18000865 DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION KIM, TAEYOON 1631 §102§103 Non-Final OA 49d overdue Pending Dec 06, 2022
17925179 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING A SARS-COV-2 INFECTION SALVOZA, M FRANCO G 1672 §103§112 Non-Final OA — Pending Nov 14, 2022
17909844 Heteromultivalent Spherical Nucleic Acids and Uses in Therapeutic and Diagnostic Applications CROW, ROBERT THOMAS 1683 §103 Non-Final OA 36d overdue Pending Sep 07, 2022
17908766 Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof WESTERBERG, NISSA M 1618 §103 Non-Final OA 67d overdue Pending Sep 01, 2022
17842433 CSF-BASED PROGNOSTIC BIOMARKERS IN ALZHEIMER'S DISEASE AND METHODS OF USE THEREOF FRITCHMAN, REBECCA M 1758 §103 Final Rejection — Pending Jun 16, 2022

Managing Emory University's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month